Serine-arginine protein kinase 1 (SRPK1) inhibition as a potential novel targeted therapeutic strategy in prostate cancer

Oncogene

Volumn 34, Issue 33, 2015, Pages 4311-4319

  Mavrou, A ^a   Brakspear, K ^a   Hamdollah Zadeh, M ^a   Damodaran, G ^a   Babaei Jadidi, R ^b   Oxley, J ^c   Gillatt, D A ^c   Ladomery, M R ^d   Harper, S J ^a   Bates, D O ^a,b   Oltean, S ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^c NORTH BRISTOL NHS TRUST   (United Kingdom)

^d UNIVERSITY OF THE WEST OF ENGLAND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; COMPLEMENTARY DNA; KI 67 ANTIGEN; NEUROPILIN 1; SERINE ARGININE PROTEIN KINASE 1; SERINE ARGININE RICH PROTEIN; SHORT HAIRPIN RNA; TUBULIN; UNCLASSIFIED DRUG; VASCULOTROPIN 165; VASCULOTROPIN A; ANGIOGENESIS INHIBITOR; ISOPROTEIN; PROTEIN SERINE THREONINE KINASE; SRPK1 PROTEIN, HUMAN; VEGFA PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC THERAPY; ARTICLE; CELL GROWTH; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR XENOGRAFT; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL MOTION; CELL PROLIFERATION; DRUG EFFECTS; METABOLISM; NEOVASCULARIZATION, PATHOLOGIC; NUDE MOUSE; PATHOLOGY; PROSTATIC NEOPLASMS; RNA SPLICING; TUMOR CELL LINE; TUMOR INVASION;

ANGIOGENESIS INHIBITORS; ANIMALS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; HUMANS; MALE; MICE; MICE, NUDE; NEOPLASM INVASIVENESS; NEOVASCULARIZATION, PATHOLOGIC; PROSTATIC NEOPLASMS; PROTEIN ISOFORMS; PROTEIN-SERINE-THREONINE KINASES; RNA SPLICING; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84939563386     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2014.360     Document Type: Article

References (39)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63: 11-30.
2. Gatta G, Mallone S, van der Zwan JM, Trama A, Siesling S, Capocaccia R. Cancer prevalence estimates in Europe at the beginning of 2000. Ann Oncol 2013; 24: 1660-1666.
3. Quaglia A, Lillini R, Crocetti E, Buzzoni C, Vercelli M. Incidence and mortality trends for four major cancers in the elderly and middle-aged adults: An international comparison. Surg Oncol 2013; 22: e31-e3824.
4. Malvezzi M, Bertuccio P, Levi F, La Vecchia C, Negri E. European cancer mortality predictions for the year 2013. Ann Oncol 2013; 24: 792-800.
5. Whang YE, Armstrong AJ, Rathmell WK, Godley PA, Kim WY, Pruthi RS et al. A phase II study of lapatinib, a dual EGFR and HER-2 tyrosine kinase inhibitor, in patients with castration-resistant prostate cancer. Urol Oncol 2013; 31: 82-86.
6. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012; 367: 1187-1197.
7. Clarke JM, Armstrong AJ. Novel therapies for the treatment of advanced prostate cancer. Curr Treat Options Oncol 2013; 14: 109-126.
8. Karantanos T, Corn PG, Thompson TC. Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches. Oncogene 2013; 32: 5501-5511.
9. Drake CG, Sharma P, Gerritsen W. Metastatic castration-resistant prostate cancer: new therapies, novel combination strategies and implications for immunotherapy. Oncogene 2014; 33: 5053-5064.
10. Folkman J, Merler E, Abernathy C, Williams G. Isolation of a tumor factor responsible for angiogenesis. J Exp Med 1971; 133: 275-288.
11. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674.
12. Ferrer FA, Miller LJ, Andrawis RI, Kurtzman SH, Albertsen PC, Laudone VP et al. Vascular endothelial growth factor (VEGF) expression in human prostate cancer: in situ and in vitro expression of VEGF by human prostate cancer cells. J Urol 1997; 157: 2329-2333.
13. Ferrer FA, Miller LJ, Andrawis RI, Kurtzman SH, Albertsen PC, Laudone VP et al. Angiogenesis and prostate cancer: in vivo and in vitro expression of angiogenesis factors by prostate cancer cells. Urology 1998; 51: 161-167.
14. Duque JL, Loughlin KR, Adam RM, Kantoff P, Mazzucchi E, Freeman MR. Measurement of plasma levels of vascular endothelial growth factor in prostate cancer patients: relationship with clinical stage, Gleason score, prostate volume, and serum prostate-specific antigen. Clinics (Sao Paulo) 2006; 61: 401-408.
15. Duque JL, Loughlin KR, Adam RM, Kantoff PW, Zurakowski D, Freeman MR. Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer. Urology 1999; 54: 523-527.
16. Bok RA, Halabi S, Fei DT, Rodriquez CR, Hayes DF, Vogelzang NJ et al. Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: a cancer and leukemia group B study. Cancer Res 2001; 61: 2533-2536.
17. Weidner N, Carroll PR, Flax J, Blumenfeld W, Folkman J. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 1993; 143: 401-409.
18. Mukherji D, Temraz S, Wehbe D, Shamseddine A. Angiogenesis and anti-angiogenic therapy in prostate cancer. Crit Rev Oncol Hematol 2013; 87: 122-131.
19. Kelly WK, Halabi S, Carducci M, George D, Mahoney JF, Stadler WM et al. Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castrationresistant prostate cancer: CALGB 90401. J Clin Oncol 2012; 30: 1534-1540.
20. Bates DO, Cui TG, Doughty JM, Winkler M, Sugiono M, Shields JD et al. VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is downregulated in renal cell carcinoma. Cancer Res 2002; 62: 4123-4131.
21. Cebe Suarez S, Pieren M, Cariolato L, Arn S, Hoffmann U, Bogucki A et al. A VEGF-A splice variant defective for heparan sulfate and neuropilin-1 binding shows attenuated signaling through VEGFR-2. Cell Mol Life Sci 2006; 63: 2067-2077.
22. Woolard J, Wang WY, Bevan HS, Qiu Y, Morbidelli L, Pritchard-Jones RO et al. VEGF165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo effect on angiogenesis and endogenous protein expression. Cancer Res 2004; 64: 7822-7835.
23. Rennel E, Waine E, Guan H, Schuler Y, Leenders W, Woolard J et al. The endogenous anti-angiogenic VEGF isoform, VEGF165b inhibits human tumour growth in mice. Br J Cancer 2008; 98: 1250-1257.
24. Harper SJ, Bates DO. VEGF-A splicing: the key to anti-angiogenic therapeutics? Nat Rev Cancer 2008; 8: 880-887.
25. Varey AH, Rennel ES, Qiu Y, Bevan HS, Perrin RM, Raffy S et al. VEGF 165 b, an antiangiogenic VEGF-A isoform, binds and inhibits bevacizumab treatment in experimental colorectal carcinoma: balance of pro-and antiangiogenic VEGF-A isoforms has implications for therapy. Br J Cancer 2008; 98: 1366-1379.
26. Bates DO, Catalano PJ, Symonds KE, Varey AH, Ramani P, O'Dwyer PJ et al. Association between VEGF splice isoforms and progression-free survival in metastatic colorectal cancer patients treated with bevacizumab. Clin Cancer Res 2012; 18: 6384-6391.
27. Amin EM, Oltean S, Hua J, Gammons MV, Hamdollah-Zadeh M, Welsh GI et al. WT1 mutants reveal SRPK1 to be a downstream angiogenesis target by altering VEGF splicing. Cancer Cell 2011; 20: 768-780.
28. Oltean S, Gammons M, Hulse R, Hamdollah-Zadeh M, Mavrou A, Donaldson L et al. SRPK1 inhibition in vivo: modulation of VEGF splicing and potential treatment for multiple diseases. Biochem Soc Trans 2012; 40: 831-835.
29. Nowak DG, Amin EM, Rennel ES, Hoareau-Aveilla C, Gammons M, Damodoran G et al. Regulation of vascular endothelial growth factor (VEGF) splicing from pro-angiogenic to anti-angiogenic isoforms: a novel therapeutic strategy for angiogenesis. J Biol Chem 2010; 285: 5532-5540.
30. Gammons MV, Federov O, Ivison D, Du C, Clark TL, Hopkins C et al. Topical anti-angiogenic SRPK1 inhibitors reduce choroidal neovascularization in rodent models of exudative-AMD. Invest Ophthalmol Vis Sci 2013; 54: 6052-6062.
31. Zhou Z, Qiu J, Liu W, Zhou Y, Plocinik RM, Li H et al. The Akt-SRPK-SR axis constitutes a major pathway in transducing EGF signaling to regulate alternative splicing in the nucleus. Mol Cell 2012; 47: 422-433.
32. Lambrechts D, Lenz HJ, de Haas S, Carmeliet P, Scherer SJ. Markers of response for the antiangiogenic agent bevacizumab. J Clin Oncol 2013; 31: 1219-1230.
33. Fukuhara T, Hosoya T, Shimizu S, Sumi K, Oshiro T, Yoshinaka Y et al. Utilization of host SR protein kinases and RNA-splicing machinery during viral replication. Proc Natl Acad Sci USA 2006; 103: 11329-11333.
34. Hayes GM, Carrigan PE, Miller LJ. Serine-arginine protein kinase 1 overexpression is associated with tumorigenic imbalance in mitogen-activated protein kinase pathways in breast, colonic, and pancreatic carcinomas. Cancer Res 2007; 67: 2072-2080.
35. Odunsi K, Mhawech-Fauceglia P, Andrews C, Beck A, Amuwo O, Lele S et al. Elevated expression of the serine-arginine protein kinase 1 gene in ovarian cancer and its role in Cisplatin cytotoxicity in vitro. PLoS ONE 2012; 7: e51030.
36. Gout S, Brambilla E, Boudria A, Drissi R, Lantuejoul S, Gazzeri S et al. Abnormal expression of the pre-mRNA splicing regulators SRSF1, SRSF2, SRPK1 and SRPK2 in non small cell lung carcinoma. PLoS ONE 2012; 7: e46539.
37. Zhou B, Li Y, Deng Q, Wang H, Wang Y, Cai B et al. SRPK1 contributes to malignancy of hepatocellular carcinoma through a possible mechanism involving PI3K/Akt. Mol Cell Biochem 2013; 379: 191-199.
38. Bates DO, Mavrou A, Qiu Y, Carter JG, Hamdollah-Zadeh M, Barratt S et al. Detection of VEGF-A(xxx)b isoforms in human tissues. PLoS ONE 2013; 8: e68399.
39. Yang M, Jiang P, Yamamoto N, Li L, Geller J, Moossa AR et al. Real-time wholebody imaging of an orthotopic metastatic prostate cancer model expressing red fluorescent protein. Prostate 2005; 62: 374-379.